MX2021013641A - Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina utiles para el tratamiento del cancer. - Google Patents
Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina utiles para el tratamiento del cancer.Info
- Publication number
- MX2021013641A MX2021013641A MX2021013641A MX2021013641A MX2021013641A MX 2021013641 A MX2021013641 A MX 2021013641A MX 2021013641 A MX2021013641 A MX 2021013641A MX 2021013641 A MX2021013641 A MX 2021013641A MX 2021013641 A MX2021013641 A MX 2021013641A
- Authority
- MX
- Mexico
- Prior art keywords
- parp2
- parp1
- tubulin
- inhibitors
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La solicitud se refiere a derivados de ftalazina de la Fórmula (I) que son inhibidores de PARP1, PARP2 y/o tubulina y, por ende, son útiles para el tratamiento del cáncer. También se describen formulaciones farmacéuticas que contienen dichos compuestos, así como también combinaciones de estos compuestos con al menos un agente terapéutico adicional.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662354449P | 2016-06-24 | 2016-06-24 | |
US201662426095P | 2016-11-23 | 2016-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021013641A true MX2021013641A (es) | 2022-01-06 |
Family
ID=59297390
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018015893A MX2018015893A (es) | 2016-06-24 | 2017-06-23 | Compuestos anti-cancer. |
MX2021013641A MX2021013641A (es) | 2016-06-24 | 2018-12-17 | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina utiles para el tratamiento del cancer. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018015893A MX2018015893A (es) | 2016-06-24 | 2017-06-23 | Compuestos anti-cancer. |
Country Status (16)
Country | Link |
---|---|
US (3) | US11072600B2 (es) |
EP (1) | EP3475272B1 (es) |
JP (2) | JP7033588B2 (es) |
KR (1) | KR102494294B1 (es) |
CN (1) | CN109843874B (es) |
AU (1) | AU2017280334C1 (es) |
BR (1) | BR112018076821A2 (es) |
CA (1) | CA3029004A1 (es) |
ES (1) | ES2964531T3 (es) |
IL (1) | IL263917B (es) |
MX (2) | MX2018015893A (es) |
PL (1) | PL3475272T3 (es) |
PT (1) | PT3475272T (es) |
SG (1) | SG11201811393WA (es) |
WO (1) | WO2017223516A1 (es) |
ZA (2) | ZA201808562B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016187620A2 (en) | 2015-05-21 | 2016-11-24 | The Regents Of The University Of California | Anti-cancer compounds |
EP3889139A1 (en) * | 2015-11-30 | 2021-10-06 | The Children's Medical Center Corporation | Compounds for treating proliferative diseases |
EP3475272B1 (en) | 2016-06-24 | 2023-09-13 | The Regents of The University of California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
US11590130B2 (en) | 2018-04-05 | 2023-02-28 | Noviga Research Ab | Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer |
CN112574122B (zh) * | 2019-09-27 | 2024-05-31 | 上海天慈国际药业有限公司 | 一种奥拉帕尼关键中间体的制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3401171A (en) | 1966-03-11 | 1968-09-10 | Smithkline Corp | 2-amidobenzimidazoles |
SU1019810A1 (ru) | 1981-07-28 | 1991-04-07 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Метиловый эфир 5(6)-[1-(2Н)-фталазинонил-4]-1Н-бензимидазолил-2-карбаминовой кислоты, обладающий антигельминтной активностью |
SU1218649A1 (ru) | 1984-09-19 | 1991-04-30 | Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского | Способ получени метилового эфира 5(6)-[1(2Н)-фталазинонил-4-]-1Н-бензимидазолил-2-карбаминовой кислоты формулы |
AU2720199A (en) | 1998-02-03 | 1999-08-23 | Boehringer Ingelheim Pharma Kg | Five-membered, benzo-condensed heterocycles used as antithrombotic agents |
KR20010101675A (ko) | 1999-01-26 | 2001-11-14 | 우에노 도시오 | 2h-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제 |
DE19907813A1 (de) | 1999-02-24 | 2000-08-31 | Boehringer Ingelheim Pharma | Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
EA006300B1 (ru) | 2000-10-30 | 2005-10-27 | Кудос Фармасеутикалс Лимитед | Производные фталазинона |
AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
GB2415430B (en) | 2003-03-12 | 2006-07-12 | Kudos Pharm Ltd | Phthalazinone derivatives |
JP4604086B2 (ja) | 2004-05-07 | 2010-12-22 | エグゼリクシス, インコーポレイテッド | Rafモジュレーターおよびその使用方法 |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
CN101291928A (zh) * | 2005-10-19 | 2008-10-22 | 库多斯药物有限公司 | 4-杂芳甲基取代的酞嗪酮衍生物 |
TWI404716B (zh) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮(phthalazinone)衍生物 |
US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
EP2271626B1 (en) * | 2008-03-27 | 2014-11-26 | Janssen Pharmaceutica, N.V. | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors |
JP5813665B2 (ja) | 2010-01-29 | 2015-11-17 | メタノミクス ゲーエムベーハー | 被験体において心不全を診断するための手段及び方法 |
CN102372706A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
EP3925962A1 (en) | 2011-05-31 | 2021-12-22 | Rakovina Therapeutics Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerase |
KR101546743B1 (ko) * | 2012-01-16 | 2015-08-24 | 한국과학기술원 | 인돌 유도체 화합물, 이를 포함하는 Abl 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물 |
WO2014102817A1 (en) * | 2012-12-31 | 2014-07-03 | Cadila Healthcare Limited | Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 |
TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
EP3475272B1 (en) | 2016-06-24 | 2023-09-13 | The Regents of The University of California | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer |
-
2017
- 2017-06-23 EP EP17737132.5A patent/EP3475272B1/en active Active
- 2017-06-23 PL PL17737132.5T patent/PL3475272T3/pl unknown
- 2017-06-23 AU AU2017280334A patent/AU2017280334C1/en active Active
- 2017-06-23 SG SG11201811393WA patent/SG11201811393WA/en unknown
- 2017-06-23 ES ES17737132T patent/ES2964531T3/es active Active
- 2017-06-23 WO PCT/US2017/039119 patent/WO2017223516A1/en unknown
- 2017-06-23 US US16/310,606 patent/US11072600B2/en active Active
- 2017-06-23 PT PT177371325T patent/PT3475272T/pt unknown
- 2017-06-23 MX MX2018015893A patent/MX2018015893A/es unknown
- 2017-06-23 IL IL263917A patent/IL263917B/en unknown
- 2017-06-23 CN CN201780051422.3A patent/CN109843874B/zh active Active
- 2017-06-23 JP JP2019519615A patent/JP7033588B2/ja active Active
- 2017-06-23 BR BR112018076821-9A patent/BR112018076821A2/pt unknown
- 2017-06-23 KR KR1020197002267A patent/KR102494294B1/ko active IP Right Grant
- 2017-06-23 CA CA3029004A patent/CA3029004A1/en active Pending
-
2018
- 2018-12-17 MX MX2021013641A patent/MX2021013641A/es unknown
- 2018-12-19 ZA ZA2018/08562A patent/ZA201808562B/en unknown
-
2019
- 2019-07-30 US US16/526,620 patent/US10640493B2/en active Active
-
2021
- 2021-07-15 US US17/376,577 patent/US20220402894A1/en active Pending
- 2021-11-26 JP JP2021192564A patent/JP2022037004A/ja active Pending
-
2023
- 2023-01-25 ZA ZA2023/01066A patent/ZA202301066B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2018015893A (es) | 2019-08-01 |
KR102494294B1 (ko) | 2023-01-31 |
CA3029004A1 (en) | 2017-12-28 |
US11072600B2 (en) | 2021-07-27 |
CN109843874A (zh) | 2019-06-04 |
US20220402894A1 (en) | 2022-12-22 |
WO2017223516A1 (en) | 2017-12-28 |
JP2022037004A (ja) | 2022-03-08 |
US20190337928A1 (en) | 2019-11-07 |
AU2017280334B2 (en) | 2021-07-29 |
ES2964531T3 (es) | 2024-04-08 |
JP2019522681A (ja) | 2019-08-15 |
CN109843874B (zh) | 2022-05-27 |
US20190352283A1 (en) | 2019-11-21 |
JP7033588B2 (ja) | 2022-03-10 |
ZA202301066B (en) | 2024-05-30 |
EP3475272B1 (en) | 2023-09-13 |
IL263917B (en) | 2022-07-01 |
EP3475272A1 (en) | 2019-05-01 |
AU2017280334A1 (en) | 2019-01-17 |
KR20190033534A (ko) | 2019-03-29 |
AU2017280334C1 (en) | 2022-10-20 |
ZA201808562B (en) | 2023-12-20 |
IL263917A (en) | 2019-02-28 |
SG11201811393WA (en) | 2019-01-30 |
PL3475272T3 (pl) | 2024-04-29 |
PT3475272T (pt) | 2023-12-15 |
US10640493B2 (en) | 2020-05-05 |
BR112018076821A2 (pt) | 2019-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502710A1 (en) | Heterocyclic compounds as immunomodulators | |
PH12019501443A1 (en) | Benzooxazole derivatives as immunomodulators | |
PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
MX2022005290A (es) | Compuestos heterociclicos como inmunomoduladores. | |
ZA202301066B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
PH12016500871A1 (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
MX2017013142A (es) | Terapia combinada para tratar cáncer. | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
MX2016004114A (es) | Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de trascripcion de choque termico 1. | |
PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. | |
PH12020500666A1 (en) | Pladienolide compounds and their use | |
WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. |